UBS Group
PMCB icon

UBS Group’s PharmaCyte Biotech PMCB Stock Holding History

UBS Group’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.19K Sell
4,142
-377
-8% -$284 ﹤0.01% 9225
2026
Q1 		$3K Buy
4,519
+1,773
+65% +$1.36K ﹤0.01% 9160
2025
Q4 		$1.99K Buy
2,746
+1,423
+108% +$1.28K ﹤0.01% 9414
2025
Q3 		$1.28K Sell
1,323
-21,269
-94% -$21.2K ﹤0.01% 9385
2025
Q2 		$24.6K Buy
22,592
+10,676
+90% +$11.9K ﹤0.01% 8304
2025
Q1 		$14.9K Buy
11,916
+10,042
+536% +$16.3K ﹤0.01% 8407
2024
Q4 		$2.94K Sell
1,874
-6,480
-78% -$11.2K ﹤0.01% 8960
2024
Q3 		$16K Sell
8,354
-19,221
-70% -$35.8K ﹤0.01% 7493
2024
Q2 		$54K Buy
27,575
+27,566
+306,289% +$59.4K ﹤0.01% 6633
2024
Q1 		$21 Sell
9
-4
-31% -$9 ﹤0.01% 9031
2023
Q4 		$29 Buy
13
+4
+44% +$9 ﹤0.01% 9047
2023
Q3 		$19 Hold
9
– – ﹤0.01% 9128
2023
Q2 		$25 Sell
9
-1,679
-99% -$5.04K ﹤0.01% 8670
2023
Q1 		$4.91K Buy
1,688
+1,679
+18,656% +$4.94K ﹤0.01% 8122
2022
Q4 		$27 Hold
9
– – ﹤0.01% 10535
2022
Q3 		$0 Hold
9
– – ﹤0.01% 10787
2022
Q2 		$0 Sell
9
-5,823
-100% -$12.7K ﹤0.01% 10779
2022
Q1 		$13K Buy
5,832
+2,171
+59% +$4.82K ﹤0.01% 8068
2021
Q4 		$9K Buy
3,661
+260
+8% +$716 ﹤0.01% 8920
2021
Q3 		$11K Buy
+3,401
New +$12K ﹤0.01% 7901

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's PMCB Position: Q2 2026 in Review

UBS Group reduced its PharmaCyte Biotech (PMCB) stake by 8.3% in Q2 2026, selling an estimated $284 and leaving 4,142 shares worth $3.19K. The position accounts for ﹤0.01% of the portfolio, ranked #9225.

UBS Group first reported a position in PMCB in Q3 2021 and has held it in 20 quarters since. The position peaked at $54K in Q2 2024. 19 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • UBS Group held 4,142 shares of PharmaCyte Biotech worth $3.19K as of Q2 2026.
  • UBS Group sold 377 PharmaCyte Biotech shares in Q2 2026, an estimated $284.
  • PharmaCyte Biotech made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9225 holding.
  • UBS Group first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 20 quarters since.
  • UBS Group's PharmaCyte Biotech position peaked at $54K in Q2 2024.
  • 19 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.